Ray Kurzweil takes more than eighty supplements daily. For Gwendolin Kirchhoff, Longevity Escape Velocity is the key concept for diagnosing the technological immortality fantasy as flight from finitude. He has published the rules for this ritual in two books and founded a company that sells the preparations: TRANSCEND Longevity Inc. The company name is no accident. What theology promised — transcendence and overcoming of mortality — is here offered as supplement. The aim: hold out long enough until medicine abolishes death. The technical term for this is Longevity Escape Velocity (LEV), the hypothetical point at which medical life-extension overtakes ageing — one year of gain per year lived.
#The calculation that has no empirical basis
The term goes back to British gerontologist Aubrey de Grey, who introduced it in 2004 in an essay in PLoS Biology (cf. de Grey, 2004). De Grey’s argumentation was a thought experiment: if medicine repairs age-damage faster than it arises, the death-threshold shifts permanently backward. Mathematically clean. Biologically unproven.
Kurzweil took up the term and gave it a date: 2032. In The Singularity Is Near (2005) nanotechnology was to pave the way — molecular robots that repair cells from inside. In The Singularity Is Nearer (2024) nanotechnology has disappeared. Now AI-supported drug development is to redeem the promise. The mechanism has fully changed. The date has stayed the same. Once you recognise this pattern you see it everywhere in the singularity movement: the date is fixed, the justification is supplied later. That is the signature of a prophecy, not a forecast.
The most ambitious animal study, the Robust Mouse Rejuvenation Project of the LEV Foundation, achieved in 2025 in mice a life-extension of 27 to 29 per cent through combined interventions (rapamycin and trametinib). That is a moderate laboratory success in rodents. From Escape Velocity — the point at which the gain durably overtakes ageing — that is as far as a glider from orbit. No peer-reviewed study has demonstrated LEV in humans even approximately.
#A billion-dollar industry of postponement
LEV is not only a forecast but a market. Altos Labs, founded in 2022, started with three billion dollars in capital, financed among others by Jeff Bezos. Calico, a subsidiary of Alphabet, has invested an estimated more than 1.5 billion dollars in longevity research since 2013. Dozens of startups, from Unity Biotechnology to Turn Biotechnologies, promise cellular reprogramming, senolytics, epigenetic rejuvenation. Kurzweil himself plans cryonics as his Plan D: have his body stored at minus 196 degrees Celsius in liquid nitrogen, should medicine not arrive in time. He speaks openly about this. The willingness to be frozen after death in the hope of a future technology that does not yet exist is no marginal detail. It is the innermost logic of LEV: a trust in future engineering achievements stronger than any present evidence.
If you look at the structure of this market, you recognise a pattern older than any biotechnology: optimistic forecasts drive investments, investments finance platforms for further forecasts, and the promise renews itself because it never has to be falsified. The deadline shifts, the mechanism changes, the promise stays. As long as death is real and the fear of it even more real, the industry finds buyers.
#What the fear of death betrays
The philosophical question lies not in whether LEV is technically possible. It lies in what the need for it says about the human being. Gwendolin Kirchhoff has diagnosed technological perfectionism as expression of a deep hostility toward life: the body is mortal, full of defects, nature inadequate. This attitude drives the wish to replace the organic by the technical, not as progress but as symptom (cf. Kirchhoff, 2022).
Jochen Kirchhoff (1944–2025) put the connection more precisely: what is sold as technical evolution is better understood as pathogenesis, as progressive symptom-development of a psycho-physical illness (cf. Kirchhoff, 2023). Transhumanism tries to push human life back into the inorganic and to fetter it there — not to overcome finitude but to eliminate it. LEV is the medical sub-promise of this larger programme: first make the body durable, then network the brain, then upload consciousness. Each step presupposes that the human being is a data set one can secure and update. That they are a living being whose mortality belongs to their form does not appear in this calculation.
The fear of death that drives LEV is not the fear of a biological event. It is the fear of oneself. In the final confrontation with dying, the human being meets their unlived life, their omissions, their truth. Whoever wants to abolish death wants to escape this encounter. Therefore it does not suffice to refute LEV empirically. The refutation changes nothing about the need. What would have to change is the relation to one’s own finitude, and that is no medical but a philosophical task.
Spengler wrote in 1931 in Man and Technics: that one was too shallow and cowardly to bear the fact of the transience of all that lives, and crawled behind ideals so as to see nothing (cf. Spengler, 1931). Kurzweil crawls behind exponential curves. The ideals have changed; the cowardice is the same.
#Escape Velocity as secularised eschatology
The structure of LEV repeats the structure of religious salvation promises: stay pious enough (take your supplements), hold out (into the 2030s), and salvation comes (medicine handles the rest). What the theosphere once delivered — the promise of a life beyond death — has migrated into the technosphere. Not the content has changed but the carrier. LEV is eschatology in the garb of biomedicine: eternal life, converted into life-years per research-year. Kurzweil’s company is called TRANSCEND. The naming is more honest than the forecast.
The promise works because it serves a real need. The human being needs transcendence — the feeling that something reaches beyond the individual death. When the old narratives lose their binding force, this need does not disappear. It migrates. LEV is one of the places where it currently arrives: transcendence, packaged as health advice, financed by venture capital, scheduled for the early 2030s.
Whoever engages with the philosophical framing of transhumanism or the concept computronium encounters the same basic structure: a need for transgression that does not recognise itself as such. The entries on singularity and technosphere deepen the cultural-diagnostic frame of this analysis.